Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 8Tumor-Agnostic 4CNS 4Genitourinary 3Gastrointestinal 3Breast 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Cardiovascular Diseases 1Breast Cancer Survivors 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Restraint, Physical × Breast × 1 year × Clear all
NCT06334354 2026-05-14

TRAC

Memorial Sloan Kettering Cancer Center

Recruiting
420 enrolled
Breast

Breast Cancer Survivors

NCT06648278 2026-01-13

COUNTS2

University of California, San Francisco

Phase NA Recruiting
260 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡